Document:

Separation Agreement by and among Alphatec Spine, Inc., Alphatec Holdings, Inc.

 Exhibit 10.23 
 SETTLEMENT AGREEMENT 
 AND MUTUAL GENERAL RELEASE 
 This Settlement Agreement and Mutual General Release (this “Agreement”) is entered into by and among Vicky A. Romanoski
(“Romanoski”), Alphatec Holdings, Inc., a Delaware corporation (“AHI”), and Alphatec Spine, Inc., a California corporation (“ASI”). Collectively, AHI and ASI and their respective subsidiaries and affiliates shall be
referred to herein as “Alphatec”, and collectively Romanoski and Alphatec shall be referred to herein as the “Parties” and individually as a “Party”. 
 1. This Agreement is entered into with reference to the following facts: 
 a. Romanoski had an employment agreement with Alphatec dated July 17, 2006, for a term of three years, subject to renewal (the “Employment Agreement”). Romanoski’s position as Senior Vice President
and Chief Administrative Officer of Alphatec terminated effective as of March 9, 2007 (the “Termination”). 
 b. In connection
with her employment, Romanoski was issued 90,825 shares of AHI common stock (the “Restricted Shares”) and 1,342 shares of AHI New Redeemable Preferred Stock (the “Restricted Preferred”), which Restricted Shares and Restricted
Preferred were subject to repurchase by Alphatec under certain circumstances. 
 c. Romanoski and/or family members own stock in AHI
purchased either as “family and friends” stock and/or in the open market (the “Open Market Shares”), which Open Market Shares are not sold, relinquished or cancelled by this Settlement Agreement and Mutual Release. 

 d. The Parties desire and hereby agree to finally settle all potential claims regarding the Termination,
as well as all other matters except as noted herein, in accordance with the terms, covenants and conditions hereinafter set forth. 
 2.
Consideration to Romanoski. 
 a. AHI shall arrange for the sale (the “Block Sale”), pursuant to Rule 144 under the
Securities Act of 1933, as amended, of such number (the “Requisite Number”) of Restricted Shares as equals (i) Three Hundred Twenty Thousand Dollars ($320,000.00) divided by (ii) the per share purchase price (without regard to
brokerage fees and commissions) in the Block Sale, and Romanoski shall retain the full amount of the proceeds of the Block Sale. 
 b. In the
event that, for any reason, the Requisite Number of Restricted Shares is not sold in the Block Sale, or the Block Sale does not occur, prior to twenty-eight days after the Effective Date (defined in Section 12(f) below), AHI shall repurchase
from Romanoski (a “Repurchase”), in cash by wire transfer of immediately available funds, such number of Restricted Shares as equals (i) Three Hundred Twenty Thousand Dollars ($320,000.00) (minus the proceeds of the Block Sale, if
any) divided by (ii) the closing price of one share of AHI common stock (as quoted on Nasdaq) on the date immediately prior to the date of the Repurchase. In the event of a Repurchase in lieu of the Block Sale, culminating in Romanoski
receiving Three Hundred Twenty Thousand Dollars ($320,000.00) in stock proceeds, AHI shall be under no further obligation to arrange for the Block Sale. In all events, whether by Block Sale, a Repurchase or any combination of the two, Romanoski
shall receive stock proceeds in the amount of Three Hundred Twenty Thousand Dollars ($320,000.00) no later than twenty-eight (28) days after the Effective Date of this Agreement AND after Romanoski delivers to Alphatec, care of its General
Counsel, Ebun Garner, stock certificates in negotiable form and all documentation reasonably necessary to effectuate the Block Sale. 

 c. Any and all fees and expenses incurred in connection with the Block Sale or a Repurchase, including
brokerage fees and commissions and the cost of counsel to render a legal opinion with respect to the Block Sale, shall be the obligation of and paid by AHI. 
 d. Romanoski shall cooperate with the Block Sale. Without limiting the generality of the foregoing, Romanoski shall deliver to Alphatec, care of its General Counsel, Ebun Garner, all of the stock certificates for the
Restricted Shares, with stock powers executed in blank. If Romanoski has lost any of her stock certificates for the Restricted Shares, then Alphatec shall reasonably cooperate with Romanoski to assist him in obtaining replacement certificates. Any
and all (ii) Restricted Shares not included in the Block Sale or a Repurchase and (ii) Restricted Preferred shall thereupon be cancelled, and Romanoski shall have no further rights or interests therein. 
 e. Upon the Effective Date, AHI shall release the Open Market Shares from any and all contractual restrictions imposed on those shares by Alphatec
pursuant to a Lock-Up Agreement or similar agreement. 
 f. Romanoski expressly acknowledges and agrees that she is not relying on any tax
advice from Alphatec with respect to the Block Sale, a Repurchase or any combination thereof, or with respect to the transaction(s) addressed in clauses a, b and c of this paragraph 2, and that she is solely responsible for any and all tax
liabilities with respect thereto. 
 3. Mutual Release. 
 a. In exchange for the promises described above, including but not limited to the transaction(s) addressed in clauses a, b and c of paragraph 2 above, and in consideration of all of the terms and conditions of this
Agreement, the Parties hereto mutually hereby and forever release and 

 
discharge each other and (as applicable) their successors, subsidiaries, parents, predecessors, affiliates, divisions, employees, owners, officers,
directors, assigns, agents, representatives, shareholders, insurers and attorneys, from any and all causes of action, actions, judgments, liens, damages, losses, claims, liabilities and demands whatsoever, whether known or unknown, which they ever
had, now have, or hereafter can, shall or may have for, upon or by reason of any act, transaction, practice, conduct, matter, cause, effect or thing of any kind whatsoever, occurring prior to the date of execution of this Agreement, including, but
not limited to, the Termination, or any act, transaction, practice or conduct or effect (a) which was alleged or asserted, or which might have been alleged or asserted, in the course of negotiating the terms of the Termination; or
(b) which arises out of, or relates in any manner to, Romanoski’s employment with Alphatec, the Employment Agreement or the Termination, including, but not limited to, any claims for: breach of contract, fraud, negligence, conversion,
misappropriation, retaliation, emotional distress, breach of the implied covenant of good faith and fair dealing, defamation, discrimination or harassment under Title VII of the Civil Rights Act of 1964, as amended, the Americans with Disabilities
Act, as amended, (the “ADA”), the Age Discrimination in Employment Act of 1967, as amended (the “ADEA”), the Older Workers Benefit Protection Act, as amended, (the “OWBPA”), the Worker Adjustment and Retraining
Notification Act, the Federal and California Family Medical Leave Acts, the California Fair Employment and Housing Act, as amended, the California Constitution, the Employee Retirement Income Securities Act, as amended, the Fair Labor Standards Act,
as amended, and any analogous California or laws or any other federal, state or local statute, ordinance, or regulation, including the California Labor Code, or any other claim, whether at common law or statutory. It is expressly agreed and
understood that this Agreement is a general release as to all matters occurring or arising before the Effective Date, including but not limited to claims for any additional shares, commissions, stock, bonuses, wages, severance or other benefits from
Alphatec. 

 b. Notwithstanding anything to the contrary in this paragraph 3 or in this Agreement, or which could be
construed to the contrary, Romanoski expressly does not release any rights or causes of action, actions, judgments, liens, damages, losses, claims, liabilities and demands whatsoever, that she had or now has or hereafter can, shall or may have,
whether fixed or contingent, liquidated or unliquidated, or in the future may have, which relate to: (1) all rights, entitlements, privileges and benefits expressly created or preserved by this Agreement, including but not limited to the Open
Market Shares, (2) all defense, indemnity, contribution and hold harmless rights, entitlements, privileges and benefits to which Romanoski is entitled under (a) common law, (b) any Alphatec bylaws or other governing corporate
documents, or (c) any of Alphatec’s insurance or indemnity policies including those covering present and former employees and/or officers, all including without limitation, with respect to claims, actions or suits by others against
Romanoski in her former status as an employee or officer of Alphatec. 
 4. Unknown Claims, Waiver of California Civil Code §
1542. The Parties understand and expressly agree that this Agreement extends to all claims of every nature and kind, known or unknown, suspected or unsuspected, past, present, or future, arising from or attributable to any conduct of the other
party and (as applicable) their successors, subsidiaries, parents, predecessors, affiliates, and divisions, and (as applicable) their shareholders, owners, employees, officers, directors, assigns, agents, representatives and attorneys, whether set
forth in any pleading or demand referred to herein or not, including but not limited to any workers’ compensation claims, and that any and all rights granted to the Parties under section 1542 of the California Civil Code or any
analogous state law or federal law or regulation, are hereby expressly WAIVED. Said section 1542 of the California Civil Code reads as follows: 

 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS
FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR. 
 5. No
Further Action. The Parties represent that they have filed no charges, claims or complaints of any kind against the other Party. The Parties further agree and covenant not to file any grievances, claims, complaints or lawsuits against any of the
persons or entities released in paragraphs 3 and 4 herein, based upon any matters released in those paragraphs. 
 6. Waiver of
Administrative Claims. The Parties acknowledges that the execution of this Agreement shall have the legal effect of withdrawing any charges or complaints the Parties may have filed with any federal, state or local agency regarding any and all
alleged wrongful conduct by persons or entities released herein occurring prior to the date of the execution of this Agreement. 
 7.
Cooperation. Romanoski agrees that with respect to any existing or future litigation, arbitration or legal dispute (“Third Party Dispute”) involving Alphatec and a third party with whom Romanoski had any connection whatsoever during
the time of her employment with Alphatec or involving any third party having a contractual relationship with Alphatec, including but not limited to any Alphatec employee or ex-employee, customer, vendor, broker, bank, or competitor, Romanoski will
reasonably cooperate with Alphatec in the defense or prosecution of that Third Party Dispute. Reasonable cooperation shall include, without limitation, providing testimony, providing assistance and information to outside counsel representing
Alphatec, and providing assistance to authorized Alphatec representatives and outside counsel in preparation for trial, hearing, arbitration or any other proceeding. Romanoski understands and agrees that she may be required to travel as part of this
duty of reasonable cooperation. Romanoski further agrees and covenants that she shall cooperate with Alphatec in responding to any unresolved or open questions or business concerns 

 
arising out of or relating to Romanoski’s business relationship with Alphatec, and that such cooperation shall not be unreasonably withheld or delayed.
In connection with any and all of the foregoing, Alphatec shall reimburse Romanoski for all of her reasonable expenses (it being understood that such expenses shall be approved by Alphatec in advance), and Alphatec and Romanoski shall mutually
determine a commercially reasonable per diem or hourly compensation to reimburse Romanoski for her time. The generality of the foregoing notwithstanding, the payment obligation set forth in the preceding sentence shall not apply to any complaint or
employment claim by Bob Lynn or any other Third Party Dispute in which Romanoski is a party or a subpoenaed witness. Under such circumstances, however, Alphatec shall still reimburse Romanoski for any reasonable expenses it approves in advance that
Romanoski incurs as part of her duty of cooperation. 
 8. Nondisparagement. 
 a. The Parties agree that they will not make any statements, written or verbal, or cause or encourage others to make any statements, written or verbal,
that defame or disparage the personal or business reputation, practices or conduct of the Parties including, if applicable, their shareholders, owners, employees, directors, officers, representatives and attorneys. The Parties acknowledge and agree
that the disparagement prohibition herein extends to statements, written or verbal, as well as any Alphatec documents and information made or delivered to anyone, including but not limited to the news media, investors, potential investors, any board
of directors or advisory board or directors, industry analysts, competitors, banks, investment banks, vendors, employees and customers. 
 b.
Romanoski covenants that upon receipt by Romanoski of the stock proceeds of Three Hundred Twenty Thousand Dollars ($320,000.00) referenced in paragraph 2 above, she and all of her agents, representatives and attorneys will return to Alphatec’s
General Counsel, and retain no copies of, each and every confidential or proprietary document, file, report and similar instrument, including 

 
all emails, that came into her possession during the course of her employment at Alphatec, with a written certification that all such materials have been so
returned. Nothing in this paragraph, however, shall be deemed to require Romanoski or her counsel to return any such document, file, report and similar instrument which constitutes or includes attorney-client privileged information and/or attorney
work product, which shall either be destroyed by Romanoski’s counsel or shall remain solely in the possession of Romanoski’s counsel, and not Romanoski. 
 9. No Future Employment with Alphatec. In exchange for the promises described above, Romanoski and Alphatec acknowledge and agree that Romanoski will not, at any future time, apply for any position with
Alphatec, or any of its affiliates, subsidiaries, divisions or parent companies that may then exist, and that in accordance with this Agreement, Alphatec has no obligation to consider such application or hire Romanoski. Romanoski agrees this
forbearance to seek future employment is purely contractual and is in no way involuntary, discriminatory or retaliatory. 
 10.
References. 
 a. If Romanoski wants to include Alphatec as a reference, the Vice President responsible for human resources at Alphatec
shall inform any person(s) making inquiries regarding Romanoski that pursuant to Alphatec policy, Alphatec can only inform them of (a) dates of employment, (b) positions held and, (c) with Romanoski’s authorization, her
compensation terms at Alphatec. 
 b. Alphatec’s internal personnel/human resources file shall reflect that Romanoski’s termination
was by mutual agreement. 
 11. Confidentiality. The provisions of this Agreement shall be held in strictest confidence by the Parties
and shall not be publicized or disclosed in any manner whatsoever; provided, however, that: (a) Romanoski may disclose the Agreement in confidence to her immediate 

 
family (provided she obtains from such immediate family member in advance their agreement to preserve the confidentiality of the information); (b) the
Parties may disclose this Agreement in confidence to their respective attorneys, accountants, auditors, tax preparers and financial advisors; (c) Alphatec may disclose this Agreement as necessary to fulfill standard or legally required
corporate reporting or disclosure requirements; and (d) the Parties may disclose this Agreement insofar as such disclosure may be necessary to enforce its terms or as otherwise required by law. 
 12. OWBPA Notification and Waiver. In accordance with the Older Workers Benefit Protection Act of 1990, 29 U.S.C. § 626(f), Romanoski
understands, acknowledges and agrees to the following and that the following is true and correct: 
 a. This waiver is part of the Agreement
between Romanoski and Alphatec, which is written in a manner that Romanoski understands; 
 b. She understands that, in signing the
Agreement, she is not waiving rights or claims that may arise after the date that this waiver is executed, except as otherwise expressly set forth in this Agreement; 
 c. She is waiving rights or claims only in exchange for consideration in addition to anything of value to which she is already entitled; 
 d. She acknowledges that she is hereby advised and has been advised in writing by Alphatec to seek the advice of counsel prior to signing the Agreement, that she has consulted with counsel, before signing the
Agreement and Romanoski is executing this Agreement only after consultation with counsel; 
 e. She acknowledges that she has the right to
have at least twenty-one (21) days within which to consider the Agreement and to decide whether to execute it. After advice of her counsel, Romanoski hereby knowingly waives any part of this twenty-one (21) day period remaining after the
date she signs this Agreement; and 

 f. She acknowledges and understands that for a period of seven (7) days following her execution of
this Agreement, she can revoke this Agreement, and this Agreement shall not become enforceable until the eighth day following the date of Romanoski’s execution of this Agreement, provided the Agreement has not been revoked prior to such date by
Romanoski (the “Effective Date”). Any such revocation by Romanoski must be in writing, signed by Romanoski and delivered to Alphatec’s General Counsel, Ebun Garner, before the close of the seven day period referenced above.

 13. Representations and Warranties. The Parties warrant and represent that (a) they have not heretofore assigned or
transferred, or purported to assign or transfer, to any person or entity, any right or claim that has been, or might have been, asserted in the Termination, or any part thereof or any interest therein, and (b) the Parties are the sole owner of
the rights and claims which are alleged in and constitute or constituted the subject matter of the Termination or claims released in paragraphs 3 and 4 above. Parties shall indemnify and hold the other party harmless from any and all liabilities,
claims, demands, actions, causes of action, damages, costs, expenses and attorneys’ fees incurred by them or any of them as a result of any breach of the foregoing warranties and representations. This indemnification shall not require a person
or entity released in paragraphs 3 and 4 herein seeking indemnification to have made payment to a third party claimant as a condition precedent to recovery of the indemnity granted herein. 
 14. Independent Legal Advice and Investigation. Each Party has received independent legal advice with respect to the advisability of entering into
this Agreement. Each Party has made such investigation of the facts pertaining to this Agreement and of all other matters pertaining hereto as she or it deems necessary. 

 15. No Admission of Liability. Each Party acknowledges and agrees that this is a compromise
settlement, which is not in any respect, nor for any purpose, to be deemed or construed to be any admission or concession of any liability whatsoever on the part of the other Party and that any such liability has been expressly denied. 

16. Further Actions. Each Party agrees to, or cause her or its counsel to, execute any additional documents and take any further action which
may reasonably be required in order to consummate this Agreement or otherwise to fulfill the obligations of the Parties thereunder. Each Party is to bear her or its own costs and attorneys’ fees incurred in connection with any such additional
action. 
 17. Modifications. No supplement, modification or amendment to this Agreement shall be binding unless executed in writing
by all Parties. No waiver shall be binding unless executed in writing by the Party making the waiver. No waiver of any of the provisions of this Agreement shall be deemed, or shall constitute, a waiver of any other provision, whether or not similar,
nor shall any waiver constitute a continuing waiver. 
 18. Choice of Law. This Agreement shall be construed and enforced in
accordance with the laws of the State of California. The Parties hereto irrevocably consent and submit to the jurisdiction of the courts of the State of California, sitting in San Diego County, as the exclusive venue for any action related in any
way to this Agreement. 
 19. Integration. This Agreement constitutes an integration of the entire understanding and agreement of the
Parties with respect to the matters referred to in this Agreement. Any representation, promise or condition, whether written or oral, between the Parties with respect to the matters referred to in this Agreement which is not specifically
incorporated in this Agreement shall 

 
not be binding upon any of the Parties and the Parties acknowledge that they have not relied, in entering into this Agreement, upon any representations,
promises or conditions not specifically set forth in this Agreement. No prior oral or written understanding, covenant, or agreement between the Parties shall survive the execution of this Agreement. Notwithstanding any of the foregoing, Romanoski
acknowledges and agrees that after the Effective Date, certain provisions of the Employment Agreement, Section 7.1 (“Proprietary Information”) and Section 7.2(b) (“Solicitation”) shall be in full force and effect and
incorporated herein by reference. To the extent there is any discrepancy between the terms of the above listed provisions and the terms of this Agreement herein, this Agreement shall control. Each Party assumes the risk of any misrepresentation,
concealment, or mistake, and if any Party should subsequently discover that any fact relied upon in entering into this Agreement was untrue, or that any fact was concealed from him or it, or that, her or its understanding of the facts or law was
incorrect, she or it shall not be entitled to set aside this Agreement. 
 20. Heirs and Assigns. The Parties understand and expressly
agree that this Agreement shall bind and benefit (as applicable) their heirs, employees, owners, officers, directors, shareholders, subsidiaries, affiliates, successors, predecessors, agents, witnesses, attorneys, representatives, and assigns.

 21. Severability. If any provision of this Agreement is held by a Court or tribunal of competent jurisdiction to be invalid, void,
or unenforceable for whatever reason, the remaining provisions shall nevertheless continue in full force and effect without being impaired in any manner whatsoever. 
 22. Counterparts. This Agreement may be executed in counterparts and, when each party has signed and delivered at least one such counterpart, each counterpart shall be deemed an original and all counterparts
taken together shall constitute one and the same agreement, which shall be binding and effective as to all Parties. The Parties may exchange signatures via facsimile or PDF and such facsimile or PDF signatures shall have the same force and
effect as if in original ink. 

 IN WITNESS WHEREOF, the parties have executed this Settlement Agreement and Mutual General Release as of
the date opposite their signatures. 
  

									
	 	 	 	 	 	 	 	 	Vicky A. Romanoski, an individual
					
	Dated:	 	June 13, 2007	 		 		 	 /s/ Vicky A. Romanoski

		 		 		 		 	Vicky A. Romanoski
					
		 		 		 		 	ALPHATEC HOLDINGS, INC.
					
	Dated:	 	June 14, 2007	 		 	By:	 	 /s/ Steven M. Yasbek

		 		 		 	Its:	 	CFO and Vice President
					
		 		 		 		 	ALPHATEC HOLDINGS, INC.
					
	Dated:	 	June 14, 2007	 		 	By:	 	 /s/ Steven M. Yasbek

		 		 		 	Its:	 	CFO and Vice PresidentSales Agency Agreement by and between Alphatec Spine, Inc. and Western Spine LLC

 CONFIDENTIAL TREATMENT REQUESTED 
  

 Exhibit 10.25 
 ALPHATEC SPINE, INC. SALES AGENCY AGREEMENT 
 This Sales Agency Agreement (the “Agreement”)
is between Alphatec Spine, Inc., a California corporation (the “Company”) and Western Spine, Inc., a Nevada corporation (Employer Identification Number
                    ) (hereinafter referred to as “Sales Agent”) is made as of February 1, 2007 (the “Effective
Date”). 
 WHEREAS Sales Agent has established and maintained a business office staffed with professional sales personnel in the
Territory (as hereinafter defined); and 
 WHEREAS the Company wishes to retain Sales Agent to sell its Products (as hereinafter defined) and
Sales Agent wishes to act as the Company’s exclusive Sales Agent within the Territory. 
 NOW THEREFORE, in consideration of the mutual
covenants and provisions herein contained, and other good and valuable consideration, the receipt and sufficiency of which is acknowledged by the parties hereto the parties agree as follows: 
  

	1.	APPOINTMENT OF SALES AGENT 

 Subject to the
provisions of the Agreement, the Company hereby appoints Sales Agent and Sales Agent hereby accepts appointment as the Sales Agent for the products described in Exhibit A (hereinafter the “Products”) with responsibility for the
geographical areas listed on Exhibit B (hereinafter the “Territory”). Sales Agent shall have the right to solicit orders for Products only from persons and entities having their places of business within the Territory that agree to
use the Products so ordered within the Territory. 
  

	2.	SALES AGENTS’ OBLIGATIONS 

 In addition to any
and all covenants, duties and obligations of Sales Agent set forth elsewhere in this Agreement, Sales Agent agrees: 
 2.1. To use its best
efforts to promote the sale of the Products throughout the Territory; 
 2.2. To use its best efforts to meet the sales quotas set forth on
Exhibit D; 
 2.3. To bear all costs and liabilities relating to the conduct of its business, including but not limited to the cost
and expense of providing and maintaining its place of business, the wages of its employees, the payment of commissions or other compensation to its agents or independent contractors, and its expenses incurred for or in connection with its
performance under or breach of this Agreement; 
 2.4. To refrain from making any representations or warranties in respect of the Products,
except: (i) those representations and warranties authorized in writing by the Company, in the form of brochures, memorandums, press releases, advertisements, specification sheets, or correspondences, and (ii) verbal technical assistance
that Sales Agent received from the Company which was subsequently confirmed in writing by Sales Agent; 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 2.5. To promote the Products in strict adherence to (i) regulatory and professional
requirements, and all applicable laws, rules, guidelines and regulations including, but not limited to, the Federal Food, Drug and Cosmetic Act of 1938, as amended, and the regulations promulgated thereunder (the “Act”); and
(ii) those portions of the Company’s Code of Conduct that address interactions with healthcare professionals (available at http://atec.client.shareholder.com/documentdisplay.cfm?DocumentID=900); 
 2.6. To render reasonable assistance to the Company, at the Company’s request, in the defense of any and all Liabilities (as defined below);

 2.7. To refrain from disparaging the Company and its subsidiaries or its Products, or from otherwise injuring the reputation and good
standing of the Company and its subsidiaries; 
 2.8. To not, directly or indirectly, solicit any sale of the Products or establish any
branch or distribution depot for the sale of the Products outside the Territory without the prior written approval of the Company within the termination date set forth herein; 
 2.9. Take full responsibility for the actions of any Sales Agent Indemnitee (as defined below); 
 2.10. To assist the Company, on request, in ascertaining the credit standing of and in collecting receivables from any customer within the Territory; and

 2.11. To attend, at its own expense, all sales meetings, training sessions, seminars, trade shows and the like for which the Company
reasonably requests attendance by Sales Agent. 
 2.12. To immediately notify the Company prior to any person who prescribes the
Company’s Products (‘the “Prescriber”) acquiring an equity interest in the Sales Agent, and upon such instance to provide in writing a listing, by percentage of equity interest owned, of all Prescribers that have an equity
interest in the Sales Agent at the time of each disclosure. A breach of this Section 2.12 shall constitute a material breach of this Agreement. 
 2.13. To deliver all Products using documented procedures for handling, storage, packing, preservation, and delivery of such Products. 
 2.14. To promptly notify the Company in writing of the following: (i) any serious regulatory action relating to the Products; (ii) any material complaints regarding the Products or the related
instrumentation; or (iii) any adverse incidents that may be subject to FDA’s (as hereinafter defined) Medical Device Reporting regulation. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 2.15. To comply with recalls or general corrective actions initiated by the Company. 
  

	3.	ALPHATEC’S DUTIES AND OBLIGATIONS 

 In order to
assist Sales Agent in fostering the promotion and sale of the Company’s Products, the Company agrees: 
 3.1. To reasonably assist Sales
Agent with advertising material, sales promotion aids, displays, catalogues, literature and convention assistance; 
 3.2. To provide Sales
Agent with new Product information and reasonably assist Sales Agent in promotional activities; 
 3.3. To provide Sales Agent with
reasonable technical assistance, through sales seminars, meetings and training programs; and 
 3.4. To use commercially reasonable efforts
to make Products available to the Sales Agent to be used by customers. 
 3.5. As long as this Agreement remains in full force and effect to
agree to not repurchase the shares of Alphatec Holdings, Inc. Common Stock and New Redeemable Preferred Stock issued pursuant to the Restricted Stock Agreement dated August 12, 2005 between Alphatec Holdings, Inc. and Scott Wiese. 

 

	4.	QUOTATIONS, ORDERS AND PAYMENT BY CUSTOMERS 

 4.1.
Sales Agent will make quotations in respect to the sales of the Products only in accordance with the Company’s then current policies and procedures and on prices established by the Company and the Company’s terms and conditions of sale,
including the terms of payment specified by the Company. The Sales Agent will provide the Company with the appropriate documentation needed for customers (credit reports, sales tax exemptions, etc.). 
 4.2. Sales orders generated by Sales Agent will be submitted directly to the Company by the customer. If Sales Agent receives any order for Products, it
will promptly forward it to the Company. The Company will establish and promulgate the criteria for sales orders to be generated by Sales Agent and Sales Agent will use its best efforts to secure sales orders that meet the Company’s criteria.
The Company will have the right at any time to reject any order in whole or in part. If the Company reasonably rejects any sales order generated by Sales Agent, then Sales Agent shall be notified and given the opportunity to inform its customer or
potential customer of said rejection in an attempt to preserve Sales Agent’s business goodwill. On request of the Company, Sales Agent will not supply Product to customers placed on credit hold until released by the Company. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 4.3. The Company will bill the customer for the purchased Products. Sales Agent will not bill
customers for the Product unless expressly requested to do so by the Company in writing. Payments against purchase orders are to be made directly to the Company, without intervention by Sales Agent unless expressly requested in writing by the
Company in each instance. If Sales Agent receives any payment from a customer, then Sales Agent will immediately forward the entire amount of such payment to the Company. 
 4.4. The Company will have the right, in its sole discretion, to issue credits, make discounts and allowances, and/or accept returns of the Products. Sales Agent in an effort to be competitive with the orthopedic
market or to develop new customers will have the right to request the Company to issue credits, make discounts and allowances and/or accept returns of the Products. The Company shall use its sole discretion in determining whether to grant Sales
Agent’s request. 
  

	5.	COMMISSIONS 

 5.1. Except as set forth in this
Agreement, during the term of this Agreement the Company will pay to Sales Agent a commission at the rate specified in Exhibit C on the Company’s Net Sales (as defined below) of Products in the Territory that were generated by the Sales
Agent in accordance with this Agreement. For purposes of this Agreement, the terms “Net Sales” shall mean, for any period, the gross amount properly set forth on a purchase order received by the Company from the customer in connection with
such customer’s purchase of Product, less deductions for: (i) normal and customary quantity and/or cash discounts, including, without limitation, those granted on account of price adjustments, rebates actually allowed and taken,
administrative or other fees or reimbursements or similar payments to buying groups, pharmacy benefit management organizations, health care insurance carriers or other institutions, fees paid to other distributors and chargebacks; (ii) freight,
postage, shipping, and related insurance expenses; (iii) customs or excise duties or other duties directly imposed and related to the sales making up the gross purchase order amount; (iv) any rebates or similar payments made with respect
to sales paid for by any governmental or regulatory authority such as, by way of illustration and not in limitation of the parties’ rights hereunder, Federal or state Medicaid, Medicare or similar state program or equivalent foreign
governmental program; (v) sales and other taxes and duties directly related to the sale of Products, to the extent that such items are included in the gross purchase order price (but not including taxes assessed against the income derived from
such sale); and (vi) any such amounts included in the purchase order that are not collected by the Company which are over 90 days past due and are recorded on the books of the Company as bad debt in accordance with generally accepted accounting
principles. For purposes of determining commissions, the Product shall be deemed to be sold when a properly executed purchase order is received by the Company from the customer in connection with such sale, and a “sale” shall not include
transfers or dispositions for charitable, promotional, pre-clinical, clinical, regulatory, or governmental purposes. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 5.2. If new product lines are added to the Product list the commission rate related to such new
Product shall be set forth on Exhibit C attached hereto within 45 days and provided to Sales Agent by the Company. The parties agree and acknowledge that the Company shall have sole decision-making authority in connection with establishing
commission rates for product lines added to the Product list after the Effective Date. 
 5.3. The Sales Agent agrees to promptly submit an
invoice to the Company in connection with each sale and that all such invoices for payment shall include a listing of all lot numbers of the Products that were sold in connection with such invoice. 
 5.4. Commissions will be released to the Sales Agent on the 30th day after the close of the month in which the applicable sales are made, or in the event
that such day is not a business day, on the next business day. Any commissions paid on outstanding accounts receivable at the close of the month that exceed the payment terms of net 90 days will be deducted from the Sales Agent’s outstanding
commission or invoiced to Sales Agent pursuant to Section 5.6. Upon collection of past due accounts commissions will be re-posted to the Sales Agent. 
 5.5. The Company will keep and maintain accurate, complete and current books and records relating to commissions earned by Sales Agent. Upon payment of commission to Sales Agent by the Company, the Company shall
provide Sales Agent with a detailed breakdown of the customer sales used to calculate the commission as well as any credit, discount, allowance or set-off taken by the Company or applied against Sales Agent commission. Any discrepancies must be
reported to the Company within 30 days of the receipt of the detailed statement. Once per calendar year, upon written request from Sales Agent, the Company will permit an independent certified public accountant designated by and at the expense of
Sales Agent to audit the Company’s books and records pertaining to commissions earned by Sales Agent, such audit to be conducted on the Company’s premises during normal business hours. 
 5.6. In the event that the Company has previously paid Sales Agent commissions on sales to a customer whose account is subsequently entitled to a credit,
for returns or otherwise, and sufficient commission is not available to deduct the credit within the period, the Company will submit an invoice and a written explanation containing the reasons why the Company is entitled to reimbursement by Sales
Agent of any portion or all of the commission previously paid to Sales Agent. Sales Agent agrees to pay all properly invoiced amounts within 30 days of receipt of said invoice. 
 5.7. The Company will have no liability whatsoever to Sales Agent for commission payments for the Company’s good faith rejection of all or part of
any order. 
  

	6.	SALES OBJECTIVE 

 6.1. The Company will establish
sales objectives for Products to be sold by the Sales Agent within the Territory as measured in dollar volume. Such sales quotas shall be set forth on 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
Exhibit D attached hereto. To the extent that a sales quota is not included in Exhibit D, the Company shall have the right to modify such
Exhibit D to include a sales quota that is proportional to the Company’s then-current annual year-to-year revenue growth rate. 
 6.2.
If new product lines are added to the Product list an additional quota will be established for such new Product and such quota shall be set forth on Exhibit D within 45 days from the date of addition. 
  

	7.	SAMPLES, PROMOTIONAL MATERIALS AND INSTRUMENTS 

 7.1. From time to time the Company may deliver to Sales Agent such items as samples, models, literature, promotional materials (the “Samples”) for use in promoting and selling the Products. Except for items actually purchased by
Sales Agent or delivered by Sales Agent as unrestricted no-charge samples according to the Company’s specific instructions, the Company will retain all right, title and interest in and to the Samples and Sales Agent will hold them in a
fiduciary capacity and only use such Samples as permitted in this Agreement. Upon the termination or expiration of this Agreement or upon the request of the Company, the Sales Agent shall return all Samples to the Company . 
 7.2. The Company will prepare and maintain accurate, complete and current books and records pertaining to the Samples that are owned by the Company,
including but not limited to type and quantity of each item and disposition thereof. 
 7.3. The Company shall establish for Sales Agent a
Products inventory account. Except for the Products actually purchased by Sales Agent, the Company will retain all right, title and interest in and to such Products and related instrumentation (the “Consigned Inventory”). Sales Agent will
hold said Products and related instrumentation in a fiduciary capacity under a separate account titled “Consigned Inventory”. 
 7.4. The Company may request a physical inventory of its property held as Consigned Inventory by Sales Agent. The Company, at its expense, may review books and records of Sales Agent as they relate to Consigned Inventory as well as to
physically audit the Consigned Inventory, and Sales Agent agrees to cooperate with such review. 
 7.5. The level of Consigned Inventory for
Sales Agent shall be established and documented upon mutual agreement between the Company and Sales Agent. 
 7.6. The level of total
Consigned Inventory for Sales Agent will be reviewed each quarter. Except to the extent that such Consigned Inventory has been consigned to a hospital in accordance with Section 7.7, if any Consigned Inventory is returned damaged, then the
Company, to the extent possible, will repair or refurbish the Consigned Inventory and invoice Sales Agent for the cost of said repairs and handling. Except to the extent that such Consigned Inventory has been consigned to a hospital in accordance
with Section 7.7, if any Consigned Inventory is lost, 
  
 CONFIDENTIAL
TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
missing, stolen, or cannot be repaired, then the Company shall invoice Sales Agent for [***]% of the list price of such Consigned Inventory, less the amount
of any commissions that would be paid for the Net Sales of such product. 
 7.7. Sales Agent will prepare and maintain complete and accurate
books and records pertaining to all Consigned Inventory, including but not limited to the type and quantity of each Product as well as the disposition thereof. Sales Agent will supply the Company with a copy of each agreement, the form of which is
attached hereto as Exhibit E, where Consignment Inventory is stocked by a hospital, on Sales Agent’s premises or other mutually acceptable place during normal business hours following ten days’ prior written notice to Sales Agent.

 7.8. Upon the termination or expiration of this Agreement, or upon the request of the Company, the Sales Agent shall immediately, and at
its own expense, return all Consignment Inventory in its possession or control to the Company. 
  

	8.	SALES ACTIVITY BY ALPHATEC 

 8.1. The Company
reserves the right, at any time and from time to time, throughout the term of this Agreement, to use its employees to engage in selling, promoting and/or other related activities concerning the Products in the Territory in the event that the Company
reasonably determines that the Sales Agent is not actively pursuing sales activities in the Territory (notwithstanding the fact that Sales Agent may be achieving its sales quotas). Any such sales by the Company’s employees will not be credited
to Sales Agent’s account for purposes of determining the achievement of sales quotas and calculating commissions. Prior to the commencement of any sales activity related to Products in the Territory by the Company’s employees, the Company
shall notify the Sales Agent of its intention to begin such activities. 
 8.2. The Company reserves the right to sell the Products within
the Territory to any person or entity offering to purchase and resell the Products as private label products so long as such person or entity is not at such time a company or person to whom Sales Agent is actually selling the Products. In the event
that private labeling occurs, if any, within the Territory, the Company may, but is not obligated to, modify Sales Agent’s sales quotas to reflect the competitive impact of private labeling. 
 8.3. The Company also reserves the right to sell the Products within the Territory to any Company-designated national, regional, or government person or
entity, and Sales Agent shall service such account within the Territory in return for the applicable commission set forth in Exhibit C. If Sales Agent declines to service any such account, the Company shall service such account itself and at
its own expense, and Sales Agent shall receive no commission with respect to such account and such sales shall not be credited to the Sales Agent for purposes of determining the achievement of sales quotas. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 8.4. The parties agree and acknowledge that under certain circumstances, the Company may find it
necessary to establish certain customers as house accounts. Justification for designation of a customer as a house account shall solely consist of any customer or Prescriber that provides written notification to the Company that such customer or
Prescriber has an unwillingness to use the services of the Sales Agent. The Company reserves the right to deal directly with such house accounts for sale of the Products, which may include delivery of the Products within the Territory, and in such
instances no commission shall be paid on sales to house accounts and such sales shall not be credited to the Sales Agent for purposes of determining the achievement of sales quotas. The Company shall pay Sales Agent such commissions as are agreed
upon between the Company and the Sales Agent for the services, if any, rendered by Sales Agent at the request of the Company in connection with sales of the Products to such house accounts that are delivered within the Territory. 
 8.5. The Company reserves the right to negotiate and establish clinical investigators and/or clinical centers to conduct clinical evaluations of the
Products within the Territory. The Company may find it necessary to implement certain remuneration programs to the clinical investigators/clinical centers as compensation for sales of the Products, which may include delivery of the Products within
the Territory. The Company shall pay such commissions to Sales Agent as are agreed upon between the Company and the Sales Agent for services, if any, rendered by Sales Agent at the request of the Company in connection with sales of Products obtained
from these clinical investigators/clinical centers located within the Territory. If no services are rendered by Sales Agent, then no commission shall be payable to Sales Agent and such sales shall not be credited to the Sales Agent for purposes of
determining the achievement of sales quotas. 
 8.6. The Company reserves the right to work with any surgeon or medical center in the design
and development of new products. The Company may find it necessary to provide special remuneration programs to the surgeon inventors/medical centers as compensation for their assistance and expertise in new product development. The Company reserves
the right to deal directly with such surgeon inventors/medical centers for the sale of Products. The Company shall pay to Sales Agent such commissions as are agreed upon between the Company and the Sales Agent for services, if any, rendered by Sales
Agent at the request of the Company in connection with sales of the Products to such surgeons/inventors/medical centers located within the Territory. If no services are rendered by Sales Agent, then no commission shall be payable to Sales Agent and
such sales shall not be credited to the Sales Agent for purposes of determining the achievement of sales quotas. 
  

	9.	RELATIONSHIP OF PARTIES 

 Sales Agent is an
independent contractor having only such authority to act for the Company as is expressly set forth in this Agreement. Sales Agent is not authorized to enter into any commitment or contract of any kind on behalf of the Company. The Company will not
incur any liability whatsoever to any third party by reason of Sales Agent having exceeded its authority 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
under the appointment granted by the Company herein or by reason of any misrepresentation by Sales Agent of its relationship to the Company or of the
Company’s products, warranties, policies, practices or procedures. Nothing contained in this Agreement is intended to be construed as creating or implying a relationship of principal and agent or employer and employee between the Company and
Sales Agent or between the Company and Sales Agent’s employees or agents, or a joint venture or partnership between the Company and Sales Agent. 
  

	10.	COMPLIANCE WITH LAWS AND REGULATIONS; NO CONFLICTS; DUE AUTHORIZATION 

 10.1 Nothing in this Agreement shall require either party to take any action which would violate any governmental regulation or law to which either of them is subject. Sales Agent shall, at its sole cost and expense,
obtain in the Territory such governmental approvals, licenses or permits as may be necessary to effectuate the purposes of this Agreement, and shall comply with all federal, state and local laws, regulations and rulings of governmental bodies having
jurisdiction over Sales Agent’s business, in respect of the sale of the Products, including, without limitation, the Act. 
 10.2 The
Sales Agent hereby represents and warrants to the Company that neither the execution of this Agreement by the Sales Agent nor the performance of this Agreement by the Sales Agent or any Sales Agent Indemnitee (as defined below) will (i) violate
any order, judgment or injunction applicable to the Sales Agent or any Sales Agent Indemnitee, or (ii) conflict with or breach any agreement to which the Sales Agent or any Sales Agent Indemnitee are a party or by which the Sales Agent or any
Sales Agent Indemnitee are bound. 
 10.3 Each party represents and warrants to the other party: (i) that such party is duly organized
and validly existing under the laws of the state of its organization and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; (ii) such party is duly authorized to execute and deliver this
Agreement and to perform its obligations hereunder; (iii) the person executing this Agreement on such party’s behalf has been duly authorized to do so by all requisite corporate action; and (iv) this Agreement is a legal and valid
obligation binding upon the parties and enforceable in accordance with its terms. 
  

	11.	REPORTS 

 Sales Agent may be requested from time to
time to submit to the Company written reports of Sales Agent’s activities performed under this Agreement. Such reports will include a listing, by name and location, of customers contacted by Sales Agent, major opportunities being pursued,
inquiries and/or problems reported by customers, physicians and/or users of the Products, Sales Agent’s recommendations respecting actions to be taken by the Company to secure sales, and any other pertinent matters requested by the Company to
be included in such reports, for the relevant period to which the report applies. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

	12.	INDEMNIFICATION 

 12.1. Sales Agent shall indemnify,
defend and hold harmless the Company, and its officers, directors, employees, affiliates and agents (the “Company Indemnitees”) from all claims, damages, losses, costs and expenses (including reasonable attorneys’ fees) (the
“Liabilities”) which any Company Indemnitee may incur to the extent that such Liabilities arise out of or result from: (i) any representation or warranty given by Sales Agent with respect to the Products (other than the labeling of
the Products as approved by the United States Food and Drug Administration (the “FDA”), (ii) the manufacture, use or sale of any product which is not supplied by Company and which is sold or combined with a Product, (iii) the
breach of any representation, warranty, or covenant of the Sales Agent contained in this Agreement; or (iv) the negligence, recklessness, gross negligence, or willful misconduct of Sales Agent or any Sales Agent Indemnitee. 
 12.2. Company shall indemnify and hold harmless Sales Agent and its officers, directors, employees, affiliates and agents (the “Sales Agent
Indemnitees”) from all Liabilities which any Sales Agent Indemnitee may incur by reason of any Products sold or furnished by Company which result in injury, illness or death to the extent that such Liabilities arise out of or result from the
failure of the Products to meet the Product warranty set forth in Section 17 or the recklessness, gross negligence, or willful misconduct of any Company Indemnitee. 
 12.3. The party seeking indemnification hereunder (the “Indemnified Party”) shall: (i) give the other party (the “Indemnifying Party”) notice of the relevant claim, (ii) cooperate with
the Indemnifying Party, at the Indemnifying Party’s expense, in the defense of such claim and (iii) give the Indemnifying Party the right to control the defense and settlement of any such claim, except that the Indemnifying Party shall not
enter into any settlement that affects the Indemnified Party’s rights or interest without the Indemnified Party’s prior written approval. The Indemnified Party shall have no authority to settle any claim on behalf of the Indemnifying
Party. 
  

	13.	CONFLICTS OF INTEREST AND ADDITIONAL RESTRICTIVE COVENANTS 

 During the time period that is the longer of [***], Sales Agent covenants that: (1) neither it nor any Sales Agent Indemnitee will engage directly or indirectly in any activity which materially conflicts with Sales Agent’s
faithful performance of the services covenants, commitments and obligations undertaken to be performed pursuant to this Agreement. Without limiting the foregoing, the Sales Agent agrees that is shall not knowingly engage or assist or induce others
to engage, directly or indirectly, in the development, production, sale, offer for sale or distribution of any third-party product which competes with either (a) any of the Products, or (b) any product being developed by the Company, of
which the Sales Agent has knowledge. For the purposes of this Section 13, a third-party product that “competes” shall mean any third party product that has the same or a similar clinical function as (a) any of the Products, or
(b) any product being developed by the Company, of which the Sales Agent has knowledge. Notwithstanding the foregoing, the Sales Agent shall be entitled to develop, produce, sell, offer for sale and distribute the products of a third party;
provided that (a) such third-party product does not compete with a 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
Product or any product being developed by the Company, of which the Sales Agent has knowledge; and (b) the Sales Agent continues to satisfy its
obligations under this Agreement, including without limitation Section 2; and (2) that without the express consent of the Company, that neither it nor any Sales Agent Indemnitee will on its own behalf or on behalf of any other person,
partnership, association, corporation or other entity, directly or indirectly solicit (either orally or in writing), or in any manner attempt to influence or induce (a) any employee of the Company to leave the employment of the Company, or
(b) any surgeon, customer, supplier or agent of the Company to terminate, modify or amend its then-current relationship with the Company in a manner that is detrimental to the Company. 
  

	14.	CONFIDENTIAL INFORMATION 

 14.1. Sales Agent
acknowledges that it will have access to certain Confidential Information (as defined below) relating to the Company or its business, including, but not limited to the internal organization of the Company; the names and responsibilities of its
management, supervisory and technical employees, operating plans, Inventions (as defined below), research and development activities, plans for acquisitions and mergers, manufacturing and/or sales activities, technical information concerning
Products and related instrumentation, trade secrets, specifications, procedures, techniques, ideas, methods, Patents (as defined below) and the names of customers and suppliers (the “Confidential Information”). 
 14.2. Sales Agent covenants that it will hold all Confidential Information confidential and shall only use such Confidential Information to satisfy its
obligations under this Agreement. During the term of this Agreement Sales Agent will be permitted, however, to disclose such part of the Confidential Information to those of its employees and/or agents as is necessary to be known by them to assist
or enable Sales Agent to perform its services and obligations under this Agreement, provided that such employee or agent has entered into a written agreement of confidentiality, the terms of which are no less rigorous than the terms set forth in
this Section 14. 
 14.3. The restrictions on use and disclosure of Confidential Information set forth in this Section 14 shall not
apply: (i) to the extent that the Confidential Information is in the public domain without fault on the part of Sales Agent or any third party not bound by an obligation of confidentiality; or (ii) disclosures that are mandated by court of
competent jurisdiction, provided that Sales Agent notifies the Company prior to such disclosure and takes reasonable actions to limit the disclosure of such Confidential Information. 
 14.4. Upon the Company’s written demand or upon expiration or termination of this Agreement, Sales Agent, at its own cost and expense, will promptly
return all Confidential Information to the Company to the extent held or controlled by Sales Agent in written, graphic or other tangible form, and all copies, summaries, notes and other write-ups thereof made by Sales Agent, or its employees and
agents. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

	15.	TERM AND TERMINATION 

 15.1. This Agreement will
become effective on the Effective Date and will continue until the [***] anniversary of the Effective Date. Upon the written agreement of the parties, this agreement may be extended for additional one-year terms. 
 15.2. This Agreement may be terminated by the Company as follows: (i) at any time upon [***] days’ written notice from the Company to the Sales
Agent; (ii) at any time during the term of this Agreement if Sales Agent fails to meet its sales quotas; (iii) at any time if Sales Agent engages in behavior that, in the Company’s reasonable determination, is materially detrimental
to the Company or its business reputation, including without limitation, a determination in the Company’s sole reasonable discretion that Prescribers have acquired too large of a percentage of the Sales Agent’s equity securities;
(iv) at any time if Sales Agent becomes insolvent or bankrupt, or files a voluntary petition in bankruptcy, or has filed for an involuntary petition in bankruptcy; or (v) at any time following the end of a 15-day cure period if Sales Agent
fails to cure any breach of a covenant, commitment or obligation under this Agreement within 15 days after receipt of written notice from the Company of such breach. 
 15.3. This Agreement may be terminated by Sales Agent as follows: (i) at any time if the Company becomes insolvent or bankrupt, or files a voluntary petition in bankruptcy, or has filed for an involuntary
petition in bankruptcy; or (ii) at any time following the end of a 15-day cure period if the Company fails to cure any breach of a covenant, commitment or obligation under this Agreement within 15 days after receipt of written notice from the
Company of such breach. 
 15.4. Following the termination or expiration of this Agreement: (i) Sales Agent shall discontinue all
promotion and distribution of the Products in the Territory; (ii) Sales Agent will not be entitled to any commissions on sales of the Products that are invoiced in the Territory after the effective date of expiration or termination of this
Agreement; (iii) the Company and Sales Agent will undertake to reconcile all matters pertaining to commission and other amounts, if any, owed by either party to the other up to the effective date of expiration or termination, as promptly as
practicable thereafter, and will settle accounts between them (including without limitation the return of all Consigned Inventory in accordance with this Agreement) in good faith not later than 60 days after the effective date of expiration or
termination of this Agreement. 
  

	16.	INTELLECTUAL PROPERTY 

 16.1. Except as granted in
this Agreement, Sales Agent has no rights in or to the Company’s trademarks, or any other trademarks, trade names or copyrights owned or used by Company (the “Trademarks”) and Sales Agent agrees that it shall not in any way infringe
upon, harm, contest or otherwise impair the rights of Company to the Trademarks. All material containing Trademarks, including all Samples, shall be used solely in connection with promoting the sale of Products, and distinguishing and identifying
them. Sales Agent may not use any Trademarks in its corporate title or the corporate title of any entity it controls. If it becomes 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 
necessary, because of conflicts with trademarks or trade names used by third parties, to develop non-conflicting marks and names for certain parts of the
Territory, Sales Agent shall so inform Company, and such new marks and names shall be developed by Company, and shall belong to Company, subject to Sales Agent’s license to use them pursuant to the terms of this Section 16. The Company, on
behalf of itself and its subsidiaries, hereby grants to Sales Agent a non-exclusive, non-transferable limited license to use the Trademarks solely in connection with its promotion, marketing and sales of the Products in the Territory pursuant to the
terms of this Agreement. Sales Agent shall have no further rights or interest in any such Trademarks. 
 16.2. Sales Agent acknowledges and
agrees that any patent on the Products acquired by the Company or any of its subsidiaries and any patent applications on the Products filed by the Company or any of its subsidiaries (the “Patents”) are the sole and exclusive property of
the Company and that throughout the term of this Agreement and following its termination or expiration, Sales Agent will not do anything inconsistent with such ownership, will not directly or indirectly challenge the title of the Company or any of
its subsidiaries to the same and will not attack the validity of such Patents. 
 16.3. Sales Agent agrees to promptly notify the Company of
any unauthorized use of the Trademarks or infringement of the Patents by others as it comes to Sales Agent’s attention. 
 16.4. Sales
Agent shall submit to the Company all inventions, discoveries and ideas concerning any modifications and improvements relating to the Products and related instrumentation (the “Inventions”). Further, all such Inventions are, and shall
remain, the sole property of the Company. Sales Agent hereby assigns to the Company all of its rights, title and interest to Inventions, and shall take such actions as is necessary to vest such rights and interests in the Company and shall require
its employees and agents to take similar actions to vest ownership of such Inventions in the Company. 
  

	17.	LIMITED WARRANTY. 

 The Company warrants that, under
normal use and service and when used in accordance with specifications supplied by Company, the Products will be of merchantable quality. If any Products do not comply with such warranty, Company will, at its option and expense, correct, repair, or
replace any defective Products provided, that, in all such cases that sufficient evidence is produced by Sales Agent to establish that the Products are defective. THE COMPANY MAKES NO OTHER WARRANTIES, EXPRESSED OR IMPLIED, WITH RESPECT TO THE
PRODUCTS AND ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE ARE EXPRESSLY AND SPECIFICALLY EXCLUDED AND DISCLAIMED. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

	18.	LIMITATION OF LIABILITY. 

 THE COMPANY’S
LIABILITY UNDER THE WARRANTY SET FORTH IN SECTION 17 OR OTHERWISE WITH RESPECT TO THE PRODUCTS OR THEIR USE (INCLUDING LIABILITY FOR CONTRACT, NEGLIGENCE OR OTHERWISE IN TORT) IS LIMITED EXCLUSIVELY TO THE REMEDY PROVIDED IN SECTION 12, AND NO OTHER
RIGHT OR REMEDY WILL BE AVAILABLE TO ANY PERSON. IN NO EVENT WILL THE COMPANY BE LIABLE TO THE SALES AGENT OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, INDIRECT, EXEMPLARY, PUNITIVE, INCIDENTAL OR CONSEQUENTIAL DAMAGES TO PERSON OR PROPERTY OR
LOSS OF PROFITS OF ANY PERSON RESULTING FROM ANY CAUSE WHATSOEVER, EVEN IF COMPANY HAS BEEN ADVISED, KNEW OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS OF PROFITS. SOME STATES AND JURISDICTIONS OUTSIDE OF THE UNITED STATES DO NOT
ALLOW A LIMITATION OR EXCLUSION OF IMPLIED WARRANTIES, OR LIABILITY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATION OR EXCLUSION MAY NOT APPLY. SALES AGENT ACKNOWLEDGES THAT THE ALLOCATION OF RISKS AND BENEFITS UNDER THIS AGREEMENT
IS BASED ON, AND THE AMOUNTS PAID UNDER THIS AGREEMENT WOULD BE GREATER IN THE ABSENCE OF, THE LIMITATIONS DESCRIBED ABOVE. 
  

	19.	MISCELLANEOUS PROVISIONS 

 19.1. This Agreement
contains the entire agreement and understanding between the parties respecting the subject matter hereof, and supersedes all prior and collateral agreements and understandings, regardless of form or nature between the parties respecting that subject
matter. 
 19.2. Other than as explicitly set forth in this Agreement, no extension, modification or supplement to this Agreement will be
effective unless made in writing and signed by a duly authorized officer of each party. 
 19.3. This Agreement will be binding upon Sales
Agent, the Company and their respective successors and permitted assigns. 
 19.4. Any notice required, permitted or contemplated by this
Agreement must be in writing, sent by facsimile, or nationally recognized overnight carrier, addressed to the other party as set forth below, or to such other address as may from time to time be substituted therefore by notice, or delivered in
person to such other party. Except as otherwise provided in this Agreement, notices sent by facsimile will be effective on the date that written confirmation of the transmission of the facsimile is received by the sender and notices sent by
overnight carrier shall be effective on the business day following written confirmation of delivery of the notice to such carrier. For purposes of notices, the addresses of the parties will be: 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

									
	If to the Company:	 	Alphatec Spine, Inc.	 	
		 	2051 Palomar Airport Road, Ste 100	 	
		 	Carlsbad, CA 92011	 	
		 	Attention:	 	Vice President, Sales	 		 	
		 	Phone:	 	760 431 9286	 		 	
		 	Facsimile:	 	760 431 1624	 		 	
				
	If to Sales Agent:	 	  
	 		 	
		 	  
	 		 	
		 	  
	 		 	
		 	  
	 		 	

 19.5. Except as provided for within this Agreement, no delay or failure by either party to enforce
or take advantage of any provision of this Agreement for non-performance or breach of any obligation hereunder by the other party, or to exercise any right hereunder, will constitute a waiver of the right of such party subsequently to enforce or
take advantage of such provision or any other provisions hereof (unless performance has been resumed or the breach has been cured by the other party) or to exercise such right or any other right hereunder, unless such waiver is in writing signed by
a duly authorized officer of the party against whom the waiver is claimed to apply, or unless the respective period for enforcement, taking advantage or exercise, as the case may be, has expired by the express terms of this Agreement. 
 19.6. This Agreement may not be assigned by Sales Agent except with the written consent of the Company and any assignment that occurs without proper
consent shall be deemed to be null and void. For the purposes of this Section 19.6, a merger of the Sales Agent with or into another entity, the sale of more than fifty percent (50%) of the Sales Agent’s equity securities in one or a
series of transactions, or the sale of substantially all of the Sales Agent’s assets shall be deemed to be an assignment. The Company may assign this Agreement by giving written notification to the Sales Agent. 
 19.7. The parties agree that the breach of this Agreement may cause irreparable harm to a party. Therefore, in addition to the other remedies specified
herein, either party may enforce its rights hereunder by all available equitable remedies, including, without limitation, the right to obtain an injunction or specific performance. 
 19.8. The Company shall not be responsible for any failure or delay in performance of its obligations under this Agreement because of circumstances
beyond its reasonable control, including, without limitation, acts of God, fires, floods, wars, civil disturbances, sabotage, accidents, labor disputes (whether or not the employees’ demands are reasonable and within the Company’s power to
satisfy), governmental actions or inability to obtain labor, material, equipment or transportation, nor shall any such failure or delay give the Sales Agent any right to terminate this Agreement. If any delivery or shipment of Products is delayed
because of any such circumstance, it shall be made as soon as possible. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 19.9. This Agreement may be executed in multiple counterparts, each of which will constitute an
original, but all of which together will constitute one and the same Agreement. 
 19.10. Notwithstanding the expiration or termination of
this Agreement for any reason, rights and obligations which by the nature should survive will remain in full force and effect. In particular the following sections shall survive the expiration or termination of this Agreement: Section 2.3,
Section 2.4, Section 2.6, Section 2.7, Section 7.8, Section 12, Section 14, Section 15.4, Section 16, Section 17, Section 18, Section 19.4, Section 19.7, Section 19.10,
Section 19.12 and Section 19.13. 
 19.11. In the event of the consummation of a Change of Control of the Company during the term
of this Agreement: [***]. 
 19.12. The validity, construction and enforcement of this Agreement and all matters related thereto or in
connection therewith all be governed by the laws of the state of California and the venue of any action brought shall be in San Diego County, California. 
 19.13. If any provision of this Agreement is rendered or declared unlawful by reason of any existing or subsequently enacted law or by decree or order of a court of last resort, the remaining provisions of this
Agreement will continue in full force and effect. 
 * * * 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above
written. 
  

			
	ALPHATEC SPINE, INC.
		
	By:	 	 /s/ M. Ross Simmonds

	Name:	 	M. Ross Simmonds
	Title:	 	Senior Vice President and Chief Operating Officer
	
	WESTERN SPINE, INC.
		
	By:	 	 /s/ Scott Wiese

	Name:	 	Scott Wiese
	Title:	 	President

  
 CONFIDENTIAL TREATMENT REQUESTED

 CONFIDENTIAL TREATMENT REQUESTED 
  

 EXHIBIT A 
 PRODUCTS 
 [***] 
  

 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 EXHIBIT B 
 LIST OF SALES AGENT’S TERRITORY 
 [***] 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 EXHIBIT C 
 COMMISSION RATE 
 [***] 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 EXHIBIT D 
 SALES QUOTAS 
 [***] 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 EXHIBIT E 
 FORM OF HOSPITAL CONSIGNMENT AGREEMENT 
 Alphatec Spine, Inc. Inventory Consignment
Agreement 
 This Inventory Consignment Agreement (the “Agreement”) is between Alphatec Spine, Inc., a California
corporation (the “Company”) and the medical institution listed on the signature page below (the “Institution”) is made as of
                    , 200     (the “Effective Date”). 
 WHEREAS the Company and the Institution have agreed to have certain of the Company’s inventory (including all related instrumentation) (the
“Consigned Inventory”) stocked at the Institution pursuant to the terms of this Agreement. 
 NOW THEREFORE, in consideration of
the mutual covenants and provisions herein contained, the adequacy of which is hereby satisfied, the parties agree as follows: 
 1. Listed
below is all of the Consignment Inventory: 
  

			
	 Item Description
	  	 Quantity

		  	
		  	
		  	
		  	
		  	
		  	
		  	
		  	
		  	
		  	

 2. Institution will hold said Consigned Inventory in a fiduciary capacity under a separate account
titled “Consigned Inventory”. 
 3. Institution shall not use the Consigned Inventory for any other purpose other than with the
consent of the Company or its authorized employees or agents. 
 4. At any time during the term of this Agreement, the Company may request a
physical inventory of the Consigned Inventory by the Institution and the Institution shall promptly respond to such request. 
  
 CONFIDENTIAL TREATMENT REQUESTED 

 CONFIDENTIAL TREATMENT REQUESTED 
  

 5. If any Consigned Inventory is returned damaged, then the Company, to the extent possible, will
repair or refurbish the Consigned Inventory and invoice the Institution for the cost of said repairs and handling. If the damaged Consigned Inventory cannot be repaired, then the Company shall invoice the Institution for 100% of the list price of
such Consigned Inventory. If any Consigned Inventory is lost, missing or stolen, then the Company shall invoice the Institution for 100% of the list price of such Consigned Inventory. In each of the instances set forth in this Section 5, upon
receipt of such invoice, Institution shall promptly remit payment to the Company. 
 6. Either party may terminate this agreement at any time
by providing written notice to the other party; provided that Section 5 and Section 7 shall survive the termination of this Agreement. 
 7. Upon the termination or expiration of this Agreement, the Institution shall immediately, and at its own expense, return all Consignment Inventory in its possession or control to the Company. 
 *        *        * 
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written. 
  

			
	COMPANY:
	
	ALPHATEC SPINE, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

			
		
	INSTITUTION:	 	
		
	(print name of Institution)	 	  

			
		
	By:	 	  

	Name (please print):
	Title:	 	

  
 CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]